#312 - Is Moderate Drinking Actually Healthy? | Dr. Tim Naimi & Mike Haney
LEVELS – A Whole New LevelShow Notes
Alcohol has spent the last 40 years bouncing between two health narratives: a little is good for your heart, or any amount is dangerous. The science doesn’t really support either slogan. Dr. Tim Naimi has spent decades studying the health effects of alcohol and, just as importantly, why the research is so difficult to interpret. His read of the evidence is less dramatic but more useful: there’s no good reason to start drinking for your health, very low intake may carry little measurable added risk, and risk rises as consumption does. Understanding why earlier studies made moderate drinking look protective helps explain a lot of the whiplashing headlines.
Free course: Improve your metabolic health Get our free email course on how glucose, nutrition, exercise, sleep, and measurement can help you build habits that support better energy and long-term health: https://levels.link/wnl
What We Cover: Why alcohol is a Group 1 carcinogen causally linked to at least seven cancers Whether small amounts of alcohol really protect your heart Why researchers still don’t have a definitive randomized trial of drinking and long-term health How the “sick quitter” problem, selection bias, and confounding made moderate drinkers look healthier Why two major recent reviews of alcohol and health produced such different headlines How the risk changes with dose, including Naimi’s estimate of a 1 in 25 lifetime risk of an alcohol-caused death at 14 drinks per week Why alcohol consumption is falling, and whether GLP-1 drugs could be contributing
🎙️ About the Guest: Dr. Tim Naimi is a physician and alcohol epidemiologist who directs the Canadian Institute for Substance Use Research at the University of Victoria, where he is a professor in the Division of Medical Sciences.
📍What Dr. Tim Naimi & Mike Haney discussed: 00:45 — Why the science on alcohol is so confusing 05:48 — How alcohol damages DNA and raises cancer risk 09:43 — Is alcohol actually good for your heart? 14:22 — Why we still don't have a definitive randomized trial 20:30 — The "sick quitter" problem 24:56 — Selection bias and the problem with "healthy" moderate drinkers 29:35 — Why two major reports produced different headlines 31:37 — How alcohol risk changes as drinks per week increase 38:21 — Industry funding and conflicts of interest 46:15 — How much alcohol is too much? 49:48 — Why younger generations are drinking less 51:53 — Health consciousness, GLP-1s, and the decline in drinking
🔗 Helpful Links: Alcohol Intake and Health Study: No Protective Effect at Low Levels, With Mortality Increasing to 1 in 25 at 14 Drinks Per Week (Journal of Studies on Alcohol and Drugs, 2026) Paper Review of Evidence on Alcohol and Health (National Academies of Sciences, Engineering, and Medicine, 2025) Report Association Between Daily Alcohol Intake and Risk of All-Cause Mortality: A Systematic Review and Meta-analyses (JAMA Network Open, 2023) Paper Do “Moderate” Drinkers Have Reduced Mortality Risk? (Journal of Studies on Alcohol and Drugs, 2016) Paper Alcohol Abstinence in Drinkers with Atrial Fibrillation (New England Journal of Medicine, 2020) Paper Canada’s Guidance on Alcohol and Health (2023) Guidance and supporting research Alcohol and Cancer (World Health Organization / IARC) WHO overview
Watch the conversation: https://youtu.be/8GNmcjPfg7U Find us on YouTube: https://youtube.com/levelshealth?sub_confirmation=1
📲 Connect: Connect with Dr. Tim Naimi at University of Victoria 👋 Who we are: Levels helps you understand your metabolic health with personalized data, expert guidance, and tools that connect your daily choices to measurable changes in your body. Our goal is to help you make better decisions about food, exercise, sleep, and long-term health.
Look for new shows every month on A Whole New Level, where we have in-depth conversations with thought leaders about metabolic health.
More from LEVELS – A Whole New Level
Heart disease is the leading cause of death, but it’s also one of the most preventable. Decades of research have established a strong causal role for LDL and other ApoB-containing particles in atherosclerosis, and we now have multiple proven ways to lower them. The harder question is how to turn that evidence into a decision for an individual person. Mike Haney talks with Johns Hopkins cardiologist Dr. Seth Martin, a co-author of the new 2026 dyslipidemia guidelines, about what the latest evidence says we should actually measure and act on. The throughline is pragmatic: lower exposure to atherogenic particles earlier and for longer, use additional tests when they can change a decision, and distinguish interesting new measurements from ones that have actually been shown to improve outcomes.
Most of NextLevel starts with a measurement problem: we can see more biology than ever, but we still have to figure out what to do with it. Bioelectronic medicine flips that sequence. We already know how to send electrical signals into the nervous system to change biology, including an FDA-approved vagus nerve treatment for rheumatoid arthritis, even though we still can’t map or read most of the individual nerve fibers carrying those signals.
Most health decisions happen before the science is settled. A study points one way, another points somewhere else, experts disagree about what matters, and even strong population-level evidence may not tell you what will happen to you.
Most medical imaging happens after a symptom, injury, or abnormal test gives a clinician a reason to look. But what changes if imaging becomes a more routine measurement, creating a record of the body before something goes wrong? In this episode of Next Level, Mike Haney talks with Dr. Daniel Durand, chief medical officer at Prenuvo, about whole-body MRI as a test case for a broader shift from episodic medicine toward longitudinal health data. Whole-body MRI is controversial, and Durand is clearly an advocate. The conversation takes the skepticism seriously, then asks a larger question: as measurement gets cheaper, more frequent, and increasingly visible to patients themselves, how should medicine decide what is worth knowing?
From a single blood sample, new proteomic tools can now measure thousands of proteins at once. Dr. Tony Wyss-Coray’s lab is using that flood of data, together with machine learning, to build a much higher-resolution picture of what’s happening throughout the body and where someone’s health may be headed.